EUCTR2011-003933-32-GBActive, not recruitingNot Applicable
A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain - The influence of ivabradine on the symptoms of neuropathic pain IISNeP
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge0 sites12 target enrollmentStarted: September 8, 2011Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Volunteers who have given written, informed consent to participate. - Volunteers who can communicate fluently in English.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
Exclusion Criteria
- •- Volunteers not giving consent to participate. - Volunteers who cannot communicate fluently in English. - Volunteers with 1 arm - Volunteers who are allergic to ivabradine, capsaicin or Tegaderm. - Volunteers for whom ivabradine is contraindicated: namely sick sinus syndrome and concomitant use of CYP3A4 inhibitors such as ketoconazole, macrolide antibiotics, nefazodone and the anti-retrovirals nelfinavir and ritonavir. - Volunteers with any rash or broken skin on the forearm where capsaicin will be applied. - Volunteers with lactose intolerance. - Volunteers with a resting pulse rate of 59 beats per minute or less at screening or on the day of the study. - Volunteers who are pregnant - Volunteers who have any underlying medical condition such as migraine or epilepsy which may affect the study findings - Volunteers who smoke, take recreational drugs or consume more than the recommended allowance of alcohol units per week
Investigators
Similar Trials
Active, not recruiting
Phase 1
A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric disease.InsomniaEUCTR2015-001672-22-DEJanssen-Cilag International NV26
Completed
Phase 2
A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric comorbidity.10040991InsomniaNL-OMON42553Janssen-Cilag8
Active, not recruiting
Not Applicable
A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric disease.InsomniaEUCTR2015-001672-22-NLJanssen-Cilag International NV26
Recruiting
Phase 2
The effects of two doses of alcohol on eye movement behaviour during drivingeurologicalNeurologicalNeurological - Other neurological disordersACTRN12623000528651Swinburne University of Technology30
Recruiting
Phase 2
The effects of alcohol on eye movement behaviour during drivingeurologicalNeurologicalEye - Normal eye development and functionNeurological - Studies of the normal brain and nervous systemACTRN12623001255673Swinburne University of Technology30